ALK(SZ:002940) Shang Hai Zheng Quan Bao·2025-11-04 19:06Core Viewpoint - The company, Zhejiang Anglikang Pharmaceutical Co., Ltd., has completed its share repurchase program, acquiring a total of 3,599,700 shares, which represents 1.78% of its total share capital, within the stipulated timeframe and budget [3][4][6]. Summary by Sections Share Repurchase Plan - The company approved a share repurchase plan on November 4, 2024, with a budget between RMB 50 million and RMB 70 million, and a maximum repurchase price of RMB 21.07 per share [2]. Implementation Details - The share repurchase was executed through a centralized bidding method, with the first purchase occurring on November 28, 2024, where 688,000 shares were acquired [3]. - By the end of the repurchase period on November 3, 2025, the company had repurchased a total of 3,599,700 shares, with a maximum price of RMB 17.00 per share and a minimum price of RMB 12.17 per share, totaling approximately RMB 50.00 million [4]. Compliance and Impact - The repurchase complied with relevant laws and regulations, ensuring no significant impact on the company's financials, operations, or shareholder interests [6]. - The repurchased shares will be used for employee stock ownership plans or equity incentives, and any unutilized shares within three years will be canceled, reducing the registered capital accordingly [10]. Trading Activity of Related Parties - During the repurchase period, the company's major stakeholders, including directors and supervisors, did not engage in buying or selling the company's shares, except for a planned reduction by a supervisor who sold 159,000 shares [7]. Regulatory Compliance - The company adhered to the regulations regarding the timing and pricing of share repurchases, ensuring no purchases were made during sensitive periods that could affect stock prices [8][9].